Information Letter on Eligard® (leuprorelin acetate depot injection): Risk of lack of efficacy due to incorrect reconstitution and administration
2014.11.28
Active substance: leuprorelin acetate
The company Astellas Pharma GmbH is circulating information on a possible lack of clinical efficacy that may occur if the product is reconstituted incorrectly.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN